Nuvalent, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
NUVL
Nuvalent, INCNuvalent, Inc. reports significant progress in its targeted oncology pipeline, including an FDA NDA acceptance for zidesamtinib and positive topline data for neladalkib, while continuing to incur substantial net losses.
NASDAQ
NUVL
Nuvalent, INC10-K: Nuvalent's 10-K Filing Reveals Progress in Cancer Therapies, Eyes First Approved Product by 2026
Nuvalent's 2024 10-K filing highlights advancements in their clinical-stage cancer therapies and reaffirms their goal to launch their first approved product in 2026.
NASDAQ
NUVL
Nuvalent, INCNuvalent Inc., a clinical-stage biopharmaceutical company, has filed its 10-K report, detailing progress in its oncology drug pipeline and outlining plans for potential product approval by 2026.